Dynamic anticancer platinum compounds
View Patent ↗A series of dynamic platinum compounds for cancer treatment are described. The compounds may become active and inactive reversibly.
1. A platinum compound comprising a structure:
wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 , independently, is hydrogen, —OH, —CH 2 —OH, —CH 2 —CH 2 —OH, —CH 2 —OH—CH 3 , —CH 2 —CH 2 —CH 2 —OH, —CH 2 —CH(CH 3 )OH, —O—CH 3 , —O—CH 2 —CH 3 , —O—CH 2 —CH 2 —CH 3 , —CH 2 —C 6 H 6 , —CH 2 ——C 6 H 5 —OH, —CH 2 —COOH, —CH 2 —CH 2 —COOH, or lower alkyl, or R 1 , R 2 , R 3 together with the attached N is pyridine;
with a proviso that when each of R 1 , R 2 , R 4 , R 5 , and R 7 is hydrogen and R 3 is t-butyl, then R 6 is not hydrogen, methyl, —CH 2 —C 6 H 6 , —CH 2 —OH, i-butyl or i-propyl;
and with a further proviso that when each of R 1 , R 2 , R 4 , R 5 , R 6 , and R 7 is hydrogen, then R 3 is not —CH 2 —COOH.
2. The compound of claim 1 , wherein the “lower alkyl” comprises a linear or branched hydrocarbon group comprising from 1 to 6 carbons.
3. The compound of claim 2 , wherein the linear or branched hydrocarbon group comprises from 1 to 3 carbons.
4. The compound of claim 1 , wherein the lower alkyl group is selected from the group consisting of methyl, ethyl, and propyl.
5. A method of treating cancer selected from the group consisting of cancer of the colon, ovaries, head and neck, brain, testicles, bladder, and combinations thereof, the method comprising administering to a cancer patient a therapeutically effective amount of the platinum compound of claim 1 .
6. A pharmaceutical composition comprising:
i) a pharmaceutically acceptable dosage form of the platinum compound of claim 1 ; and
ii) one or a plurality of pharmaceutically acceptable excipients.
7. A method of treating cancer selected from the group consisting of cancer of the colon, ovaries, head and neck, brain, testicles, bladder, and combinations thereof, the method comprising administering to a cancer patient a therapeutically effective amount of the pharmaceutical composition of claim 6 .
8. The method of claim 7 , wherein said pharmaceutically acceptable dosage form comprises between about 5 mg and about 1000 mg of said platinum compound.
9. The method of claim 8 , wherein said pharmaceutically acceptable form is administered once every one to four weeks.
10. The method of claim 9 , wherein administration is repeated until remission of said cancer is observed.
11. The method of claim 7 , wherein said pharmaceutical composition is administered orally.
12. The method of claim 7 , wherein pharmaceutical composition is administered parenterally.
13. The method of claim 7 , further comprising administering to said cancer patient a further chemotherapeutic agent selected from the group consisting of verapamil, podophyllotoxin, procarbazine, mechlorethamine, cyclophosphamide, camptothecin, ifosfamide, melphalan, chlorambucil, bisulfan, nitrosurea, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin, etoposide (VP16). tamoxifen, taxol, transplatinum, 5-fluorouracil, vincristin, vinblastin, methotrexate, and combinations thereof.
14. The method of claim 13 , further comprising administering to said cancer patient a radiation selected from the group consisting of X-ray radiation, UV-radiation, γ-radiation, microwave radiation, and combinations thereof.
15. The method of claim 7 , wherein said administering is effected by local delivery of said pharmaceutical composition.
16. The method of claim 7 , wherein said administering is effected by direct injection of a tumor in said cancer patient with said pharmaceutical composition.
17. The method of claim 7 , wherein said administering comprises delivering said pharmaceutical composition endoscopically, intratracheally, intralesionally, percutaneously, intravenously, subcutaneously, intratumorally or by combinations thereof.
18. The method of claim 7 , further comprising resectioning a tumor in said cancer patient prior to said administering.
19. A method of treating AIDS comprising administering orally or parenterally to an AIDS patient a therapeutically effective amount of a pharmaceutical composition comprising the platinum compound of claim 1 .